Sangamo Therapeutics, Inc.
NASDAQ: SGMO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae Ch.B
- Employees
- 183
- Headquarters
- Richmond, United States
- IPO year
- 2000
- Market cap
- $29.0M
- Website
- https://www.sangamo.com
Loading SGMO…
Loading profile data…Frequently asked questions about SGMO
What does Sangamo Therapeutics, Inc. (SGMO) do?
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is...
Where does SGMO trade?
Sangamo Therapeutics, Inc. (SGMO) trades on the NASDAQ Global Select.
What sector is SGMO in?
Sangamo Therapeutics, Inc. (SGMO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sangamo Therapeutics, Inc.?
Alexander D. Macrae Ch.B is the chief executive officer of Sangamo Therapeutics, Inc. (SGMO).
Where is Sangamo Therapeutics, Inc. headquartered?
Sangamo Therapeutics, Inc. is headquartered in United States.
Does SGMO pay a dividend?
Sangamo Therapeutics, Inc. (SGMO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SGMO go public?
Sangamo Therapeutics, Inc. (SGMO) completed its initial public offering in 2000.